No drug has been shown to be able to arrest or slow down the process of this condition. There is promise that two drugs, tafamidis and diflunisal, may improve the outlook, since they were demonstrated in randomized clinical trials to benefit patient affected by the related condition FAP-1 otherwise known as<unk> -related hereditary<unk> osis. Permanent pacing can be employed in cases of symptomatic slow heart rate (bradycardia). Heart failure medications can be used to treat symptoms of difficulty breathing and congestion. An investigational first-in-human study has demonstrated that NTLA-2001, a therapeutic agent based on the CRISPR-Cas9 system, induces targeted knockout of the<unk>  protein. Orphan drug status for<unk>  (TTR)<unk> osis Because of preliminary data suggesting the drug may have activity, the U.S. FDA has granted tolcapone "orphan drug status" in studies aiming at the treatment of<unk>  familial<unk> osis (ATTR). However, tolcapone is not FDA approved for the treatment of this disease.
Wild-type transthyretin amyloid
Alpha-synuclein
Amyloid beta
Immunoreactive trypsinogen
Anti-gliadin antibodies
Keratic precipitate
Kamino bodies
Anchoring fibrils